Ann: Imugene completes $35M Placement & Launches c.$30M SPP, page-362

"Curing Cancer is a big deal. A really big deal."

Come on dude. Plenty of CAR-T and B-cell based approaches out there, in the US particularly (many autologous ones like J&J's CARVYKTI already in market helping patients). None of them are curing cancer. They will give hope and hopefully prolonged life in the ongoing battle to many patients with poor prognosis.

Pick any similar angled US company and you will see a massive drop off from late 2021 Fed money, sprinkled with cancer curing euphorically driven highs. Realism creeping in.

I am tempted to buy into IMU at these levels, but its still a long shot and a very long wait on commercial success. Azer-cel clearly holds synergies for IMU, but if it was such a shoo-in, why is the seller selling at such a low price and moving purely into gene editing?

IMU's noble venture for an off the shelf allogeneic CAR T Product for CD19+ CAR T relapsed patients is to be applauded, but IMU investors would do well to take a good look at MSB and its efforts in an allogeneic stem cell product for steroid refractory GVHD patients (basically kids pretty much not living much past 2 years) and its difficulties in getting FDA approval. The CAR T-cell field is a far more competitive market to boot.

I suspect IMU and MSB will get there eventually, but neither are curing cancer.